Financial targets

Bioretec's board of directors decided on 4 October 2024 to update the company's product development strategy by accelerating the product development of the RemeOs™ Spinal Interbody Cage following the granting of Breakthrough Device Designation status by the US Food and Drug Administration on 14 March 2024.
 

As of 4 October 2024, Bioretec's financial targets are:

• reach net sales of EUR 65 million by the end of the year 2028 and to reach net sales in excess of EUR 100 million by the end of the year 2030; and
• reach positive cash flow from operating activities by the end of the year 2027.
   

Bioretec's previous financial targets were:

• To reach net sales of EUR 62 million by the end of the year 2027 and
• To reach positive cash flow from operating activities by the end of the year 2026.